Clinical trials: Human Papilloma Virus (HPV), open to volunteers
Cervical Cancer Screening, Human Papilloma Virus
Developing and Implementing HPV SCREENED
This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED).
- Trial name
- NCT07657104
- Testing
- HPV Self-collection in the ED
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Squamous Cell Carcinoma of the Head and Neck, Oropharynx
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Background: Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy
- Trial name
- NCT06223568
- Testing
- Docetaxel, Cisplatin, PRGN-2009
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus (HPV) Vaccines
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low.
- Trial name
- NCT03429413
- Testing
- Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
- Where
- United States
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of Florida
Human Papillomavirus Associated Carcinomas, Cervical Cancer
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
- Conditions
- Human Papillomavirus Associated Carcinomas, Cervical Cancer, Head and Neck Cancers, Anal Cancer
- Trial name
- NCT06544720
- Testing
- SCG142 TCR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma.
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT04564989
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Oropharynx Cancer
De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers
The goal of this clinical trial is to learn whether for intermediate-risk patients who have undergone Transoral Robotic Surgery for HPV/p16(+) oropharyngeal cancer and have minimal smoking history, whether these patients can be…
- Trial name
- NCT06554158
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Human Papilloma Virus
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
Human Papillomavirus (HPV) infection is the most common sexually transmitted infection in the world. It is currently estimated that 4.5% of all cancers worldwide are attributable to HPV, representing 630,000 new cases per year.
- Trial name
- Cohorte_HPV (NCT05566106)
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Oropharyngeal Cancer, Human Papilloma Virus
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic…
- Conditions
- Oropharyngeal Cancer, Human Papilloma Virus, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05582590
- Testing
- Fludarabine, Cyclophosphamide, NEXI-003 T cells
- Volunteers
- 36 people
- Sponsor
- NexImmune Inc.
CIN 2/3
Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer
NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral…
- Trial name
- NeoART-CIN (NCT07095478)
- Testing
- Artesunate
- Where
- 5 sites in Malaysia
- Volunteers
- 28 people
- Sponsor
- Metanoic Health Ltd.
Human Papilloma Virus (HPV), Hearing Disability
Knowledge and Beliefs of Hearing Impaired Individuals Regarding Human Papillomavirus (HPV)
Health education is one approach to influencing individuals, groups, or communities to achieve better health. The literature indicates that increasing awareness of HPV, along with participation in early screening and vaccination…
- Trial name
- HPV (NCT07207655)
- Testing
- HPV Card Game
- Volunteers
- 40 people
- Sponsor
- Çankırı Karatekin University
Cervical Cancer, Human Papilloma Virus (HPV)
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
The goal of this study is to test two commercially available technologies for their ability to detect treatment response in patients with cervical cancer following surgery, radiation, and chemotherapy: one based on polymerase…
- Trial name
- NCT07214584
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Florida
Head and Neck Cancer, Oropharynx Cancer
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated…
- Conditions
- Head and Neck Cancer, Oropharynx Cancer, Human Papilloma Virus
- Trial name
- SHORT-OPC (NCT04178174)
- Testing
- SABR boost and de-escalated chemoradiation, Standard chemoradiation
- Where
- 2 sites in Canada
- Volunteers
- 360 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Common Warts (Verruca Vulgaris), Common Warts
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4.
- Conditions
- Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-4 (NCT07457918)
- Testing
- Cantharidin
- Where
- 12 sites in United States, Japan
- Volunteers
- 250 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma.
- Trial name
- NCT05046080
- Testing
- Electronic Health Record Review, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
Squamous Cell Carcinoma of Oropharynx
Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention
Prospective pilot study, non-interventional, of a biological/radiological nature, which involves the collection of tissue samples, and blood from patients suffering from squamous cell carcinoma of the oropharynx OPSCC for…
- Trial name
- NCT06821243
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Regina Elena Cancer Institute
Oropharyngeal Carcinoma
A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for…
- Trial name
- NCT06984861
- Testing
- 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
- Where
- 7 sites in United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Carcinoma
Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer
Our institution recently began incorporating a novel "tongue-out" radiation therapy (TORT) technique for patients with head and neck tumors at particular subsites (oropharynx, larynx, hypopharynx). Protruding the tongue, i.e.
- Trial name
- NCT07227792
- Testing
- Tongue-out radiation therapy (TORT)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yvonne Mowery
Human Papillomavirus Infection
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids.
- Trial name
- NCT07888686
- Testing
- 10vHPV, Gardasil9
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.